Biotech Diagnostics & Imaging Products

Latest News: Seeing Into Deep Tissue

04-13-2023

Published April 13, 2023. Prof. Hongjie Dai, Stanford professor and Nirmidas co-founder, is interviewed by Nature Photonics to discuss the latest development on bioimaging in the second near-infrared (NIR-II) spectral window and its clinical potential.

MORE>

Nirmidas Has Obtained 12-Month Shelf Life for MidaSpot® COVID-19 Antibody Combo Detection Kit

11-09-2021

To comply with regular shelf-life testing updates imposed by the FDA for MidaSpot® COVID-19 Antibody Combo Detection Kit to be maintained as an Emergency Use Authorization (EUA) product, the following lots have been extended until the new dates as shown below: Kit Lot NumberTest Card Lot NumberNew Expiration Date15933159322022.01.1716203162012022.01.3016401163992022.08.15 The FDA letter can be vi

MORE>

Nirmidas Biotech Receives FDA Emergency Use Authorization for its COVID-19 Rapid Antibody Fingerstick Test

01-05-2021

Click Here for News on Businesswire Click Here for News on 360 DXLearn More about MidaSpot COVID-19 Antibody Combo Detection Kit How to Purchase MdiaSpot COVID-19 Antibody Combo Detection Kit

MORE>

Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations

Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between vaccines.

A New Saliva-Based Lateral-Flow SARS-CoV-2 IgG Antibody Test for mRNA Vaccination

Sensitive detection of IgG antibodies against SARS-CoV-2 is important to assessing immune responses to viral infection or vaccination and immunity duration. Antibody assays using non-invasive body fluids such as saliva could facilitate mass testing including young children, elderly and those who resist blood draws, and easily allowing longitudinal testing/monitoring of antibodies over time.

Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing

Antibody cross-reactivity confounds testing for dengue virus (DENV) and Zika virus (ZIKV). We evaluated anti-DENV and anti-ZIKV IgG detection using a multiplex serological platform (the pGOLD assay) in patients from the Asunción metropolitan area in Paraguay, which experiences annual DENV outbreaks but has reported few autochthonous ZIKV infections.